PACS Group, Inc. · NYSE
Zacks Investment Research
PACS Group, Inc. (PACS) Surges 6.2%: Is This an Indication of Further Gains?PACS Group shares jumped 6.2% to $47.75 on investor optimism ahead of Q3 2026 earnings release. The company is expected to report 75% earnings growth and 8.1% revenue growth. However, with unchanged consensus EPS estimates over the past 30 days, analysts caution that the stock may lack momentum for sustained gains without positive estimate revisions.
Zacks Investment Research
Medpace (MEDP) Q3 Earnings and Revenues Beat EstimatesMedpace (MEDP) reported Q3 2026 earnings of $4.84 per share, beating consensus estimates of $4.45, with revenues of $716 million exceeding expectations by 1.02%. However, the stock has underperformed the S&P 500 year-to-date, gaining 10.8% versus the market's 12.7%.
The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical Services industry ranks in the bottom 34% of Zacks industries.
Headlines link to the publisher. Not investment advice.
Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
No sentiment yet
Sign in to post on $PACS
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.
